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Abstract
Introduction: B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) are members of the
tumor necrosis factor (TNF) family that regulate B-cell maturation, survival, and function. They are overexpressed in
a variety of autoimmune diseases and reportedly exist in vivo not only as homotrimers, but also as BLyS/APRIL
heterotrimers.
Methods: A proprietary N-terminal trimerization domain was used to produce recombinant BLyS/APRIL
heterotrimers. Heterotrimer biologic activity was compared with that of BLyS and APRIL in a 4-hour signaling assay
by using transmembrane activator and CAML interactor (TACI)-transfected Jurkat cells and in a 4-day primary
human B-cell proliferation assay. A bead-based immunoassay was developed to quantify native heterotrimers in
human sera from healthy donors (n = 89) and patients with systemic lupus erythematosus (SLE; n = 89) or
rheumatoid arthritis (RA; n = 30). Heterotrimer levels were compared with BLyS and APRIL homotrimer levels in a
subset of these samples.
Results: The recombinant heterotrimers consisted mostly of one BLyS and two APRIL molecules. Heterotrimer
signaling did not show any significant difference compared with APRIL in the TACI-Jurkat assay. Heterotrimers were
less-potent inducers of B-cell proliferation than were homotrimeric BLyS or APRIL (EC50, nMol/L: BLyS, 0.02; APRIL,
0.17; heterotrimers, 4.06). The soluble receptor fusion proteins atacicept and B-cell maturation antigen (BCMA)-
immunoglobulin (Ig) neutralized the activity of BLyS, APRIL, and heterotrimers in both cellular assays, whereas B-cell
activating factor belonging to the TNF family receptor (BAFF-R)-Ig neutralized only the activity of BLyS. In human
sera, significantly more patients with SLE had detectable BLyS (67% versus 18%; P < 0.0001), APRIL (38% versus 3%;
P < 0.0002), and heterotrimer (27% versus 8%; P = 0.0013) levels compared with healthy donors. Significantly more
patients with RA had detectable APRIL, but not BLyS or heterotrimer, levels compared with healthy donors (83%
versus 3%; P < 0.0001). Heterotrimer levels weakly correlated with BLyS, but not APRIL, levels.
Conclusions: Recombinant BLyS/APRIL heterotrimers have biologic activity and are inhibited by atacicept and
BCMA-Ig, but not by BAFF-R-Ig. A novel immunoassay demonstrated that native BLyS/APRIL heterotrimers, as well
as BLyS and APRIL homotrimers, are elevated in patients with autoimmune diseases.
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B-lymphocyte stimulator (BLyS)-also called B cell-acti-
vating factor belonging to the tumor necrosis factor
family (BAFF)-and a proliferation-inducing ligand
(APRIL) are members of the tumor necrosis factor
(TNF) family and are important regulators of B-cell
maturation, survival, and function [1,2]. The TNF
ligands generally form trimeric structures composed of
three monomers [3]. Heterotrimers of BLyS and APRIL
have also been shown to exist in vivo,a n dah i g h e r -
order oligomer of BLyS homotrimers has been reported
[4-6].
BLyS homotrimers bind to the B cell-expressed recep-
tors transmembrane activator and CAML interactor
(TACI), B cell-maturation antigen (BCMA), and BAFF
receptor (BAFF-R), whereas APRIL homotrimers bind to
TACI, BCMA, and proteoglycans [7,8]. The binding of
BLyS and APRIL to these receptors activates specific
TNF receptor-associated factors (TRAFs), which regu-
late signal transduction in B cells. The interaction with
TRAFs induces the nuclear factor (NF)-B signaling
pathway, which plays a pivotal role in regulating diverse
aspects of immune function, including mediating inflam-
matory responses and facilitating adaptive immunity
[9-11]. The binding of BLyS and APRIL to TACI,
BCMA, and BAFF-R receptors also triggers the upregu-
lation or downregulation of members of the Bcl-2 family
of proteins, which are involved in cell death, prolifera-
tion, survival, and cell-cell interactions [12]. It has been
proposed that signaling through TACI in mature B cells
or plasmablasts requires higher-order BLyS oligomers or
the cross-linking of APRIL through its binding to pro-
teoglycans, whereas BAFF-R and TACI on primary B
cells can bind and respond to all forms of BLyS [4,8,13].
BLyS and APRIL are overexpressed in the sera of
patients with a wide variety of autoimmune disorders,
including systemic lupus erythematosus (SLE) [14,15]. In
patients with rheumatoid arthritis (RA), BLyS and
APRIL are overexpressed in the synovial fluid as well as
in the sera [6,16]. Preliminary data suggest that BLyS/
APRIL heterotrimers also are elevated in patients with
various autoimmune conditions [6]. In light of their
roles in B-cell function and these clinical data, BLyS and
APRIL are targets for novel treatments for autoimmune
diseases.
Atacicept is a fully human recombinant fusion protein
comprising the extracellular portion of the TACI recep-
tor linked to an Fc domain of immunoglobulin (Ig)G.
Atacicept modulates B cells by neutralizing BLyS and
APRIL activity and is in clinical development for the
treatment of SLE and RA [17,18]. As BLyS/APRIL het-
erotrimers may also be elevated in patients with autoim-
mune diseases, it is important to determine whether
these heterotrimers play a particular biologic role, and if
therapies targeting BLyS and APRIL will also neutralize
BLyS/APRIL heterotrimers. This study investigated the
in vitro activity of recombinant heterotrimers in cell-sig-
naling and proliferation assays, and the ability of the
soluble B cell-expressed receptors atacicept, BCMA-Ig,
and BAFF-R-Ig to neutralize heterotrimer activity. A
bead-based immunoassay was developed for BLyS/
APRIL heterotrimers, and endogenous levels of hetero-
trimers in the sera of healthy donors and patients with
SLE or RA were measured and compared with BLyS
and APRIL homotrimer levels in a subset of the same
samples.
Materials and methods
Production of recombinant BLyS and APRIL homotrimers
and BLyS/APRIL heterotrimers
BLyS and APRIL homotrimers were generated as pre-
viously described [19,20]. Recombinant BLyS/APRIL
heterotrimers were produced by using a proprietary N-
terminal trimerization domain [21]. The Flag-zippered
(zz) 12.6 form of APRIL [21] and the Hisx6-zz12.6 form
of BLyS were made by overlap polymerase chain
reaction (PCR) of human APRIL [amino acids 110-250]
template and human BLyS [amino acids 141-285] tem-
plate, respectively. The assembled cDNA was inserted
by homologous recombination into the vectors pZMP21
[22] and pZMP41z, respectively, downstream of the
optimized tissue plasminogen activator (otPA) leader
sequence. These vectors were transfected into protein-
free media-adapted Chinese hamster ovary (CHO)
DXB11 cell suspension by electroporation, and the cells
were selected for growth in methotrexate- and copper-
chelated antibiotic (Zeocin)-containing medium.
Methotrexate- and Zeocin-resistant cells were stained
with fluorescein isothiocyanate-anti-CD8 and phycoery-
thrin-anti-CD4, and CD8
+/CD4
+ cells selected by
fluorescence-activated cell sorting. Batches of the BLyS/
APRIL heterotrimer were produced in a 10-L WAVE
bioreactor. Both BLyS and APRIL were quantified by
Western blot with anti-His and anti-Flag antibodies,
respectively, as described later. The expression levels of
B L y SN H 6z z 1 2 . 6a n dA P R I LN F zz12.6 were approxi-
mately 10 mg/L and 33 mg/L, respectively.
Purification of recombinant BLyS/APRIL heterotrimers
Heterotrimers were purified from CHO-conditioned
media after buffer exchange to phosphate-buffered saline
(PBS) (pH 7.4) by ultrafiltration/diafiltration and loading
onto an immobilized metal affinity chromatography NI-
NTA His Bind Superflow Column (Novagen, Gibbstown,
NJ, USA). A heparin affinity column (HAC), Heparin AF-
650M (Tosoh Bioscience, Montgomeryville, PA, USA),
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APRIL via NaCl gradient elution. The HAC eluate was
concentrated to < 8 ml and injected over a size-exclusion
chromatography (SEC) Superdex 200 Prep Grade Col-
umn (GE Healthcare, Piscataway, NJ, USA).
Generation of non-tagged recombinant BLyS/APRIL
heterotrimers
Non-tagged heterotrimers were produced by using a
limited proteolysis strategy with trypsin to cleave the
Flag and His tags from the zz12.6 heterotrimers. A
HAC (as earlier), was used to resolve non-tagged hetero-
trimer from undigested products by NaCl gradient elu-
tion. The HAC eluate was concentrated to < 3 ml and
injected over an SEC column (as earlier). The SEC elu-
ate was incubated and rocked slowly overnight with 1
ml of anti-Flag agarose resin (Sigma, St Louis, MO,
USA). The resin was separated from solution via 0.22-
μm filtration. N-terminal sequence analysis, SEC with
multiangle light scattering (SEC-MALS), and Western
blot analyses were consistent with both tags having been
removed.
Protein detection
APRIL or BLyS protein samples were visualized by using
nonreducing sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Analysis with Western
blotting was performed by using standard methods. The
anti-APRIL blot comprised anti-Flag horseradish peroxi-
dase (HRP) for the Flag-zz12.6 form, and anti-APRIL
polyclonal antibody (pAb) followed by donkey anti-rab-
bit IgG-HRP for the trypsinized form of APRIL. The
anti-BLyS blot comprised anti-6x His HRP for the
Hisx6-zz12.6 form of BLyS, and anti-BLyS pAb followed
by donkey anti-rabbit IgG-HRP for the trypsinized form
of BLyS. The molecular mass of the heterotrimers was
confirmed by SEC-MALS mass distribution LS/UV/RI
3-detector analysis.
Binding kinetics and affinity studies
The binding affinities and kinetics of BLyS (average
values were determined from three distinct lots of pro-
tein), APRIL (six lots), and heterotrimers (one lot) for
the receptor-Fc fusion proteins (atacicept, BCMA-Ig,
and BAFF-R-Ig) were assessed with Biacore surface plas-
mon resonance studies by using a Biacore 3000 analyzer
(GE Healthcare) equipped with Biacore Control, Evalua-
tion, and Simulation software version 3.2.
Atacicept, BCMA-Ig, and BAFF-R-Ig were covalently
immobilized onto a Biacore CM4 sensor chip. Binding
affinity studies were performed at 25°C with a 50 μl/min
flow rate for varying ligand concentrations. Serial 1:2
dilutions of each ligand from ~0.05 to 20 nMol/L were
made in analysis buffer (20 mmol/L sodium phosphate,
150 mmol/L NaCl, 0.05% polysorbate 20, pH 7.5). Disso-
ciation constant (KD) values were determined from the
k i n e t i cr a t ec o n s t a n t s( ka and kd). The binding curves
were processed by double referencing and were globally
fitted to a 1:1 binding model. The stoichiometry of bind-
ing was not determined.
Biologic activity assays
A 4-hour signaling assay was performed by using TACI-
transfected Jurkat cells carrying an NF-B/luciferase
reporter gene (KZ142). TACI/KZ142-Jurkat cells (1 ×
10
5 cells/well) were incubated at 37°C for 4-6 hours
with recombinant BLyS, APRIL, or heterotrimer in a
t o t a lw e l lv o l u m eo f1 0 0μl in complete RPMI-1640
media without phenol red, and in the absence or pre-
sence of atacicept, BCMA-Ig, or BAFF-R-Ig in concen-
trations ranging from 0.001 to 100 nMol/L. After
incubation, 100 μl/well of Steady-Glo reagent was
added, and the plates were foil covered and agitated at
r o o mt e m p e r a t u r ef o r1 0m i n u t e s .T h ea s s a yp l a t ew a s
then analyzed in a luminometer to measure luciferase
activity.
For the human B cell-proliferation assay, B cells from
two healthy donors were isolated from peripheral blood
mononuclear cells by negative selection with the human
B Cell Isolation Kit II from Miltenyi Biotec (Auburn, CA,
USA), according to the manufacturer’s instructions. Flow
cytometry confirmed that they were > 97% pure (CD19
+).
The purified B cells (5 × 10
4 cells/well) were plated in a
96-well flat-bottomed plate pre-coated with 5 μg/ml anti-
IgM monoclonal antibody (mAb) (Southern Biotech, Bir-
mingham, AL, USA) in media containing 10 ng/ml
recombinant human interleukin-4 (R&D Systems, Min-
neapolis, MN, USA) and BLyS, APRIL, or heterotrimer
at concentrations ranging from 0.001 to 100 nMol/L.
The plates were then incubated for 4 days at 37°C, and
proliferation was determined by
3H-thymidine incorpora-
tion assay. To determine the relative neutralization with
the soluble receptors, atacicept, BCMA-Ig, or BAFF-R-Ig,
the assay was set up as previously described by using
50% effective concentrations (EC50) of BLyS, APRIL, and
heterotrimers (1, 3, and 10 nMol/L, respectively). Starting
with a 300-fold molar excess, 1:4 serial dilutions of ataci-
cept, BCMA-Ig, or BAFF-R-Ig were then added to
the wells, and the assay run as described earlier. Fifty
percent inhibition concentration (IC50)v a l u e sw e r e
determined for the inhibition of ligand activity by each
soluble receptor by using purified B cells from a third
donor.
Please see Supplemental Methods in Additional file 1
for more-detailed descriptions of the generation, purifi-
cation, and characterization of the recombinant hetero-
trimers, and of the binding affinity and biologic activity
assays.
Dillon et al. Arthritis Research & Therapy 2010, 12:R48
http://arthritis-research.com/content/12/2/R48
Page 3 of 14Generation of anti-APRIL and anti-BLyS monoclonal
antibodies
Anti-human APRIL mAbs were generated from BALB/c
mice immunized with 50 μg of recombinant Flag-zz12.6
APRIL in combination with Ribi-CWS adjuvant (Corixa-
Sigma, St Louis, MO, USA) every 2 weeks over an
8-week period. Serum titers were determined for the
presence of anti-APRIL antibodies. The mice with the
most significant anti-APRIL serum titers were immu-
nized a final time. Four days later, the spleen and lymph
nodes of the mice were harvested and fused to mouse
myeloma P3-X63-Ag8.653 cells (American Type Culture
Collection) at a 1:1 lymphocyte/myeloma ratio with
polyethylene glycol 1500 by using standard methods.
Wells of the fusion plates were fed 3 times with a 70%
replacement of media, and wells were assayed 10 and 12
days after the plating of the fusion for anti-APRIL anti-
bodies. Anti-human BLyS mAbs were prepared as
described earlier, except that 20 μgo fb a c u l o v i r u s - p r o -
duced His-zz12.6 BLyS was used for the initial immuni-
zations followed by 10-μg maintenance boosts. Antibody
purifications were performed from hybridoma superna-
tant by Protein G (GE Healthcare) affinity chromatogra-
phy followed by pH elution.
Heterotrimer immunoassay
After pre-wetting and blocking a Luminex plate with
assay buffer (PBS with 0.05% Tween 20, 1% bovine serum
albumin), 5 × 10
3 anti-APRIL capture mAb-coated
beads/well were added to the plate in 25 μl/well assay
buffer. To this, 25 μlo fs t a n d a r dp l u s2 5μlo fn o r m a l
human serum (pre-screened for low heterotrimer levels)
or 25 μl of sample serum plus 25 μl of assay buffer was
added. The plate was incubated on a shaker for 1 hour at
room temperature, and then washed twice with 100 μlo f
assay buffer. Biotinylated anti-BLyS antibody (25 μl/well)
was added, and the plate was incubated again as
described earlier. Streptavidin-phycoerythrin (25 μl) was
then added at 1:200 in assay buffer and incubated on a
shaker for 30 minutes at room temperature. The plate
was washed twice with 100 μl of assay buffer. Wells were
then resuspended in 100 μl of assay buffer and analyzed
by using a Luminex 100 machine (Luminex Corporation,
Austin, TX, USA). The total assay time was 2 hours. The
a s s a yh a dab r o a dr a n g e( ~ 1 0 0p g / m lt o2 5n g / m l )w i t h
an EC50 of ~6 ng/ml.
Luminex-based assays may vary in sensitivity due to
differences in the capture-bead lots used. In this study,
the heterotrimer assay data were generated by using two
lots of beads with slightly different limits of quantitation
(LOQs), 0.100 ng/ml versus 0.313 ng/ml. To make use
of the combined dataset, the most conservative LOQ
(0.313 ng/ml) was applied to all heterotrimer data,
although some sample cohorts had reportable values
below this concentration (see Supplemental Tables 1
and 2 in Additional file 2).
Serum heterotrimer and BLyS and APRIL homotrimer
levels in patients with autoimmune diseases
Serum samples from 30 patients with SLE and 30
patients with RA were obtained from the University of
Washington (Seattle, WA, USA) serum repository. Dr.
Dall’Era and Dr. Wofsy from the University of Califor-
nia, San Francisco (UCSF) (San Francisco, CA, USA)
provided 59 serum samples from 47 patients with SLE
and from nine healthy donors. Twenty of the UCSF
serum samples from patients with SLE were collected
from the same eight patients over time (two to four
draws each, drawn a minimum of 1 month apart). All
patients fulfilled the revised American College of Rheu-
matology classification criteria for SLE and RA. Patients
were enrolled after obtaining their written informed
consent by using a protocol approved by the Human
Subjects Committee of the University of Washington
and the Committee on Human Research at UCSF,
respectively. Serum samples from an additional 80
healthy donors were collected at ZymoGenetics, Inc.
(Seattle, WA, USA).
Serum samples from healthy donors (n = 89) and
patients with SLE (n = 89) or RA (n = 30) were col-
lected in ethylenediaminetetraacetic acid (EDTA) tubes
and frozen at -80°C. Samples were thawed and assessed
for native heterotrimer levels by using the heterotrimer
immunoassay described earlier. BLyS and APRIL levels
were measured in a subset of the serum samples from
healthy donors (n = 40) and patients with SLE (n = 30).
BLyS levels were measured with enzyme-linked immu-
nosorbent assay (ELISA), as described previously [18].
All samples were measured in triplicate. As assay perfor-
mance criteria, a precision of 20% for the coefficient of
variation in the patient samples was accepted. The LOQ
was 0.78 ng/ml of BLyS in the serum. APRIL levels were
determined by using an ELISA developed and validated
at ZymoGenetics, Inc. (Seattle, WA, USA) [20]. The
LOQ was 2 ng/ml of APRIL in the serum. Because of
insufficient volume, one of 30 available SLE serum sam-
ples and one of 40 healthy donor samples could not be
included for assessment in the APRIL ELISA.
Statistical methods
All statistical analyses were performed by using Prism 4
for Windows (GraphPad Software, Inc., La Jolla, CA,
USA). The proportions of serum samples with BLyS or
A P R I Lh o m o t r i m e ro rB L y S / A P R I Lh e t e r o t r i m e rl e v e l s
above the assay LOQ in patients with SLE or RA were
compared with those for the healthy donor cohort by
using Fisher’s exact test. A value of P < 0.05 was consid-
ered to be statistically significant. To reduce the impact
Dillon et al. Arthritis Research & Therapy 2010, 12:R48
http://arthritis-research.com/content/12/2/R48
Page 4 of 14of data skewing, correlation analysis for BLyS, APRIL,
and heterotrimers levels was assessed by using Spear-
man’s rank correlation coefficient. For the correlation
analysis and for data plotting, samples with serum ligand
levels below the assay LOQ were assigned values equal
to half of the LOQ for each assay (0.39, 1.0, and 0.156
ng/ml for BLyS, APRIL, and heterotrimer, respectively).
Bivariate correlation plots were generated by using JMP
software (SAS Institute, Inc.).
Results
Characterization of heterotrimers
The recombinant BLyS/APRIL heterotrimers were char-
acterized by SDS-PAGE and Western-blot analyses
(Figure 1). The molecular mass and purity of the hetero-
trimers were confirmed by SEC-MALS analysis (Figure 2).
Because of unequal BLyS and APRIL expression plasmid
efficiencies (see Materials and methods), the recombinant
heterotrimers had a predominant stoichiometry of
2A P R I Lt o1B L y S( A 2B), and thus consisted of only
a small fraction of 1 APRIL to 2 BLyS (AB2) heterotri-
mers. The ratio of ~66.3% APRIL and 33.7% BLyS was
identified by Western blot, and confirmed by SEC-MALS
analysis.
The binding affinities of BLy S ,A P R I L ,a n dh e t e r o t r i -
mers for the soluble receptor fusion proteins atacicept,
BCMA-Ig, and BAFF-R-Ig, were determined from one
or two surface plasmon resonance experiments for each
ligand. BLyS (n = 2) was the only ligand that exhibited
binding to BAFF-R-Ig (KD = 0.02-0.07 nMol/L). BLyS
(n = 2), APRIL (n = 2), and heterotrimers (n = 1) bound
to atacicept (KD = 0.02 nMol/L [BLyS], 0.1-0.2 nMol/L
Figure 1 Sodium dodecylsulfate polyacrylamide gel electrophoresis and Western blot analysis of (a) BLyS/APRIL heterotrimer and (b)
trypsinized (nonzippered) heterotrimer. APRIL, a proliferation-inducing ligand; BLyS, B-lymphocyte stimulator.
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(KD = 0.3 nMol/L [BLyS], 0.0001-0.0003 nMol/L
[APRIL], and 0.01 nMol/L [heterotrimers]).
Biologic activity and neutralization of heterotrimers
Heterotrimer signaling was similar to that of APRIL in
the in vitro TACI-Jurkat assay (Figure 3a). Trypsinized
versions of the heterotrimers and APRIL that lacked the
proprietary “zipper” trimerization domain needed for
their efficient expression were equally as active as the zz
versions. This suggested that the zipper domain did not
alter the biologic activity of these ligands in this assay.
Atacicept and BCMA-Ig neutralized the activity of BLyS,
APRIL, and heterotrimers in the TACI-Jurkat assay
(Figure 3b). As expected, BAFF-R-Ig only neutralized
the activity of BLyS.
The heterotrimers were less-potent inducers of B-cell
proliferation than were BLyS or APRIL, as evidenced by
the higher EC50 values for heterotrimers than those of
BLyS or APRIL in the primary human B cell-prolifera-
tion assay (Figure 4a). In the neutralization assay, BAFF-
R-Ig inhibited BLyS but exhibited little to no inhibition
of heterotrimer or APRIL activity on human B cells
(Figure 4b).
Heterotrimer immunoassay
To address whether endogenous heterotrimers are pre-
sent in the sera of patients with autoimmune diseases,
the recombinant heterotrimers were used as a standard
to develop a bead-based immunoassay by using anti-
APRIL capture mAb and fluorescence-labeled anti-BLyS
detection mAb to quantify native heterotrimers in
human sera. The bead-based assay used a recombinant
protein heterotrimer that was heavily skewed toward
A2B BLyS/APRIL trimers as a reference standard, but
nevertheless, was also able to detect AB2 trimers. During
the assay, beads conjugated with an anti-APRIL mAb
were incubated with the test sample and washed, and
then bead-bound heterotrimers were detected with a
biotinylated anti-BLyS detection mAb. This format
allowed the detection of both A2Ba n dA B 2 native het-
erotrimers. We confirmed that the new assay detected
BLyS/APRIL heterotrimers but did not detect BLyS or
APRIL homotrimers (Figure 5).
Heterotrimer, BLyS, and APRIL levels in patients with
autoimmune diseases
The heterotrimer immunoassay and previously reported
ELISAs for BLyS and APRIL were used to measure
native heterotrimer, BLyS, and APRIL levels in serum
samples from healthy donors and patients with SLE or
RA (Figure 6a and Table 1). Significantly more patients
with SLE had detectable heterotrimers in sera (27%, P =
0.0013) compared with healthy donors (8%), whereas
detectable heterotrimer levels were found in only 7%
(P = nonsignificant) of the samples from patients with
RA (Table 1).
Analyses of BLyS and APRIL homotrimer levels were
performed in a subset of the samples from healthy
donors and patients with SLE, and for all of the samples
from patients with RA (Figure 6a and Table 1). In sera
from patients with SLE, significantly more samples had
detectable BLyS (67%; P < 0.0001) and APRIL (38%; P <
0.0002) levels compared with the healthy donor cohort
(18% (BLyS) and 3% (APRIL)) (Figure 6a and Table 1).
Strikingly, although APRIL was detectable in most sam-
ples for patients with RA (83%; P < 0.0001) compared
with healthy donors (3%), no statistically significant dif-
ference in detectable levels of BLyS was found in
patients with RA (33%) compared with the healthy
donor samples (18%) (Table 1). Within the samples con-
taining detectable levels of the three ligands, no obvious
Figure 2 Size-exclusion chromatography with multiangle light-scattering mass distribution of purified HT. Red line, molecular weight
species by static light scattering; blue line, BLyS/APRIL HT; APRIL, a proliferation-inducing ligand; BLyS, B-lymphocyte stimulator; HT, heterotrimer;
MW, molecular weight.
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APRIL, or heterotrimers levels in healthy donors com-
pared with the mean values of each ligand in patients
with SLE or RA, with the possible exception of elevated
APRIL levels in patients with RA (Table 1). The mean
detectable heterotrimers levels were generally similar to
or lower than the BLyS and APRIL levels in the same
patient cohorts (Table 1). Notably, in one sample from a
patient with RA in which all three ligands were detect-
able, heterotrimer levels (5.37 ng/ml) exceeded those of
APRIL (2.87 ng/ml), but not of BLyS (58.9 ng/ml).
A weak correlation was found between BLyS and het-
erotrimer levels (Spearman r = 0.2328, P <0 . 0 2 )i n
samples for which data for both ligands were available
(Figure 6b, upper panel). No correlations were present
between APRIL and heterotrimer levels or APRIL and
BLyS levels (Figure 6b, middle and lower panels, respec-
tively). Interestingly, in the 98 samples for which data
on all three ligands were available, 43 had detectable
levels of only one ligand: 22 with APRIL, 16 with BLyS,
and five with heterotrimers. Two samples from patients
with RA and one sample from a patient with SLE had
detectable levels of all three ligands, whereas samples
from six patients with SLE had detectable levels of both
BLyS and heterotrimers. In contrast, levels were below
the LOQ for all three ligands in the majority of samples
Figure 3 (a) Biologic activity and (b) neutralization of BLyS/APRIL HTs compared with those of BLyS and APRIL in TACI-Jurkat
proliferation assays. APRIL, a proliferation-inducing ligand; BAFF-R, BAFF receptor; BCMA, B cell-maturation antigen; BLyS, B-lymphocyte
stimulator; EC50, 50% effective concentration; HT, heterotrimer; IC50, 50% inhibition concentration; Ig, immunoglobulin; nz, trypsinized trimer
without the “zipper” domain; TACI, transmembrane activator and CAML interactor; zz, trimer containing the “zipper” trimerization domain.
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were available (27 of 36, 75%) (Figure 6 and data not
shown).
Correlation between heterotrimer levels and disease
activity markers for patients with SLE
A subset of the samples from patients with SLE used in
the heterotrimer assay had previously been assessed for
various markers of disease activity, including patient
SLE Disease Activity Index (SLEDAI) scores at the time
of serum draw, erythrocyte sedimentation rate (ESR),
concentrations of anti-double stranded DNA (dsDNA)
antibodies, and levels of the complement components
C3 and C4. Although this information was available for
a relatively small group of these samples (n = 36), the
data were analyzed to seek any potential correlations
between serum heterotrimer levels and other markers of
SLE disease activity. The 36 samples from patients with
Figure 4 (a) Biologic activity and (b) neutralization of BLyS/APRIL HTs compared with those of BLyS and APRIL in B cell-proliferation
assays. BLyS, APRIL, and heterotrimers were used at concentrations of 1 nMol/L, 3 nMol/L, and 10 nMol/L, respectively. APRIL, a proliferation-
inducing ligand; BAFF-R, BAFF receptor; BCMA, B cell-maturation antigen; BLyS, B-lymphocyte stimulator; CPM, counts per minute; EC50, 50%
effective concentration; HT, heterotrimer; IC50, 50% inhibition concentration; Ig, immunoglobulin; TACI, transmembrane activator and CAML
interactor.
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heterotrimer levels found in each sample: undetectable,
low, and high heterotrimer levels. The median heterotri-
mer concentration in the 27 positive samples was 0.227
ng/ml; all samples with heterotrimers levels above this
v a l u ew e r ea s s i g n e dt ot h e“high” heterotrimer group.
Typically, as the SLE disease state worsens, patients’
serum C3 and C4 levels decrease, whereas SLEDAI
scores, anti-dsDNA antibody levels, and ESR all
increase. We observed a trend suggesting that heterotri-
mer levels increase along with SLEDAI, anti-dsDNA
antibodies, and possibly ESR (Supplemental Tables 1
and 2 in Additional file 2). C3 and C4 levels were also
lower in samples with detectable heterotrimer levels,
compared with those samples with undetectable hetero-
trimer levels.
Discussion
In this study, recombinant BLyS/APRIL heterotrimers
were produced by using a novel trimerization domain,
purified, and extensively characterized. Their biologic
activity was evaluated in vitro, and the effect of atacicept
and other related soluble receptors on their activity was
determined. A novel immunoassay was developed, and
the occurrence of endogenous heterotrimers in healthy
donors and patients with SLE and RA was demon-
strated. Heterotrimer levels were compared in a subset
of the patient samples with levels of homotrimeric BLyS
and APRIL.
Several trimeric forms have been proposed for BLyS
and APRIL. In principle, BLyS/APRIL heterotrimers
could be any mix of stoichiometries (A2Bo rA B 2). The
heterotrimers produced for this study were predomi-
nantly A2B, and their biologic activities were more simi-
lar to APRIL than to BLyS. The A2Bs t o i c h i o m e t r yw a s
obtained because of the characteristics of the two vec-
tors that were used to express BLyS and APRIL in the
production cell lines. In vivo, BLyS/APRIL heterotrimers
are likely to be formed stochastically in cells in which
both BLyS and APRIL are generated, and the relative
production of these proteins may influence the propor-
tion of A2Ba n dA B 2 heterotrimers that are endogen-
ously formed. Furthermore, BLyS and APRIL appear to
be differentially regulated [16,23-25], and their levels
may even be inversely correlated [23], which is also sug-
gested by a trend in our limited dataset of patient
samples.
Differential TACI, BCMA, and BAFF-R receptor
expression may favor biologic activity of the A2Bv e r s u s
the AB2 heterotrimers. The highest-affinity binding was
observed between APRIL and BCMA-Ig, which was up
to three orders of magnitude greater than observed for
BLyS or heterotrimer binding to atacicept, BCMA-Ig, or
BAFF-R-Ig. In the TACI-Jurkat assay, heterotrimer sig-
naling was similar to that of APRIL homotrimers. The
reduced potency of the heterotrimer ligands in the pri-
mary human B cell-proliferation assay compared with
the homotrimeric BLyS may be explained by the predo-
minant expression on circulating B cells of BAFF-R, to
which our heterotrimers bind poorly owing to their pre-
dominantly A2B stoichiometry. Differences between
receptor expression and/or B cell composition in the
blood from different donors may explain the complex
differences in dose-response curves observed in the pri-
mary B-cell assay.
Roschke et al. [6] also investigated the ability of solu-
ble Ig fusion versions of TACI, BCMA, and BAFF-R to
neutralize BLyS and BLyS/APRIL heterotrimers in a
human B cell-proliferation assay. In that study, only
TACI-Ig inhibited the BLyS/APRIL heterotrimer, and
BCMA-Ig or BAFF-R-Ig was ineffective [6]. In our stu-
dies, both atacicept and BCMA-Ig neutralized the activ-
ity of BLyS, APRIL, and the recombinant BLyS/APRIL
heterotrimer in the TACI-Jurkat and human B cell-pro-
liferation assays, whereas BAFF-R-Ig inhibited BLyS but
exhibited little or no inhibition of heterotrimer or
APRIL activity. This was expected and consistent with
the observed binding of BLyS, but not APRIL, to BAFF-
R. It could be hypothesized that the Roschke et al.h e t -
erotrimers were composed of predominantly AB2 tri-
mers; however, it is difficult to explain why these
heterotrimers were not inhibited by soluble BAFF-R-Ig.
This discrepancy would best be addressed by specifically
purifying A2Ba n dA B 2 heterotrimers, and assessing
their activity in the presence of each of the three soluble
receptors. We would speculate that native A2B trimers
are likely capable of binding to TACI and BCMA,
whereas AB2 trimers should predominantly bind to
TACI and possibly BAFF-R.
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oligomers (for example, 60-mers) composed of multiple
homotrimers, a cluster formation mediated by a flap-like
region that is not present in APRIL [5]. Although some
early reports showed that BLyS existed in vivo only in
trimeric form [26,27], a more recent study suggested
that BLyS 60-mers may form naturally in vivo and have
biologic activity distinct from that of BLyS homotrimers
[4]. However, no reports have been published of native
oligomeric APRIL. It has been proposed that signaling
through TACI in mature B cells or plasmablasts
requires higher-order BLyS oligomers or the cross-link-
ing of APRIL through its binding to proteoglycans,
whereas BAFF-R and TACI on primary B cells can bind
and respond to all forms of BLyS [4,8,13]. Our BLyS
homotrimers signal less strongly than APRIL and the
heterotrimers in the TACI-Jurkat assay, leading to a 20-
to 25-fold difference in EC50 values between BLyS and
APRIL or the heterotrimers. This finding appears to
support the contention that BLyS oligomers may be
required for optimal signaling through TACI. However,
after extensive evaluation of the recombinant BLyS,
APRIL, and heterotrimers using SEC-MALS and other
techniques, we found no evidence for higher-order mul-
timers or oligomerization of the ligands in this study
(data not shown).
The inhibition of BLyS, APRIL, and the heterotrimers
by atacicept is consistent with the observed effects of
atacicept and/or murine TACI-Ig in preclinical and clin-
ical studies. In mice and monkeys, atacicept reduces
serum IgM levels and inhibits the IgM response to T-
dependent antigen [28]. It inhibits B-cell maturation and
survival, age-related T-cell activation, and the T cell-
independent marginal zone B-cell response, and signifi-
cantly decreases levels of plasma cells in the spleen and
bone marrow [28-30]. However, atacicept does not
reduce the numbers of B memory cells, which are active
in long-term humoral immunity, as their survival is
independent of BLyS or APRIL [31]. These biologic
changes in response to atacicept are associated with
reduced disease scores and prolonged survival in SLE-
prone mice [19,29,30,32]. In Phase Ib studies, subcuta-
neous atacicept treatment reduced serum Ig, mature B-,
and total B-cell levels in patients with RA or SLE
[17,18]. These actions were coupled with promising
exploratory effects on disease-activity measures
[17,18,33]. Phase II/III trials are currently assessing the
efficacy and tolerability of atacicept in patients with
these conditions.
Our patient cohort data support and expand on a pre-
vious report showing higher serum levels of BLyS/
APRIL heterotrimers in a limited sample of patients
with autoimmune diseases (n = 15) compared with
healthy controls (n = 6) [6]. Roschke et al. [6] investi-
gated whether BLyS/APRIL heterotrimers are elevated
in patients with autoimmune diseases, and reported
levels of up to ~230 ng/ml [6]. In the Roschke et al.
study, a mAb reagent capable of immunoprecipitating
the heterotrimers was identified, and an assay was per-
formed to measure heterotrimers by using an ELISA
strategy. Data were reported from two separate ELISA
assays, using either the anti-heterotrimer mAb or an
anti-BLyS pAb as capture antibodies to quantify the pro-
teins in patient sera. In several cases, data from the two
assays differed by an order of magnitude for the same
sample. The authors postulated that the higher hetero-
trimer levels were detected with the pAb assay because
of better capture abilities than the mAb-based assay, or
ap o s s i b l ep r e f e r e n c ef o re i t h e rt h eA 2Bo rt h eA B 2
forms of the heterotrimers. In contrast, the immunoas-
say described in the current study was designed to
detect both the A2B and AB2 forms of the heterotrimers,
and heterotrimer levels were quantified by using laser
detection of fluorescently labeled detection mAbs. The
results from our assay suggest that the levels of hetero-
trimers in vivo, even in very ill patients, are similar to or
lower than those of the homotrimeric forms of BLyS
and APRIL, with serum concentrations of native hetero-
trimers observed that were typically < 5 ng/ml. How-
ever, although heterotrimer levels are typically
somewhat lower than those of the homotrimers, in cer-
tain patients, they may be found in similar or even
Table 1 Serum heterotrimer, BLyS, and APRIL levels in healthy donors, and patients with SLE or RA
Heterotrimer BLyS APRIL
Patients Number of samples
with > LOQ
n/N (%)
Mean ± SD
a
(ng/ml)
Number of samples
with > LOQ
n/N (%)
Mean ± SD
a
(ng/ml)
Number of samples
with > LOQ
n/N (%)
Mean ± SD
a
(ng/ml)
Healthy donors 7/89 (7.8) 0.83 ± 0.61 7/40 (17.5) 3.91 ± 3.47 1/39 (2.6)
b 2.35 ± 0
SLE 24/89 (26.9) 0.52 ± 0.19 20/30 (66.7) 3.28 ± 2.35 11/29 (37.9)
b 2.31 ± 0.18
RA 2/30 (6.7) 2.85 ± 3.55 10/30 (33.3) 8.07 ± 18.0 25/30 (83.3) 3.15 ± 1.44
aMean concentration for serum samples with detectable ligand levels.
bIn the subset of serum samples available, one sample from a healthy donor and one from a patient with SLE were not assayed because of insufficient volume.
LOQ, limit of quantitation; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus.
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terized assays are needed to assess accurately the relative
levels of BLyS, APRIL, and heterotrimers, and to deter-
mine how common elevations are in their levels in clini-
cal populations.
In the serum samples from patients with SLE and RA
used in this study, levels of BLyS, APRIL, and heterotri-
mer were elevated in patients with SLE, compared with
the sera of healthy donors. The detection of a single
ligand (BLyS, APRIL, or heterotrimer) in more than one
third of the samples may reflect specific control mechan-
isms for these TNF family members. The available data
also suggest a trend toward correlation of BLyS and het-
erotrimer levels in patients with SLE, although this result
is based on a very small number of samples with levels
above the assay LOQ for both ligands.
It should be noted that, although our analysis shows
that APRIL is detectable in a higher fraction of patients
with SLE than in healthy controls, some controversy
exists with regard to the role of APRIL in SLE. Several
studies [6,14,24] have shown that APRIL levels are ele-
vated in patients with SLE. Koyama et al. [14] showed a
trend between APRIL levels and anti-dsDNA Ab levels
and a correlation with the British Isles Lupus Assess-
ment Group (BILAG) index score of musculoskeletal
disease. In contrast, Stohl et al. [24] reported an inverse
correlation between APRIL and anti-dsDNA Ab levels
and disease activity measured by SLEDAI score. Another
recent study reported high APRIL levels in the sera of
patients with SLE, but no correlation with SLEDAI
s c o r e[ 2 3 ] .T h eu s eo fd i f f e r e n tA P R I La s s a y sm a yc o n -
tribute to the disparate results currently in the literature,
as some assays (including ours) show serum APRIL con-
centrations of 2-8 ng/ml (see, for example, Planelles
2004 (34)), whereas other assays yield much higher
values, ≤ 2,500 ng/ml [14,16,23,35-37]. A possible expla-
nation for these discrepancies is the biochemical charac-
teristics of the recombinant APRIL used to generate
capture and detection reagents and to provide reference
standards for each assay. In our experience, some com-
mercially available forms of APRIL, when used as refer-
ence standards, yield inaccurate (high) or imprecise
determinations of native APRIL levels in sera (unpub-
lished observations).
The present analysis of our limited RA patient cohort
s h o w st h a tA P R I Lm a yb es p e c i f i c a l l ye l e v a t e di nR A ,
whereas BLyS or heterotrimer levels do not appear to be
increased. Others have previously reported that levels of
both BLyS and APRIL in patients with RA are higher in
synovial fluid than in serum, suggesting that these
ligands play an important role in the inflamed synovial
compartment [15,16,38]. It would be of interest to
repeat these studies of matched RA serum and synovial
fluid samples by using our APRIL assay.
Our analysis of the subset of serum samples from
patients with SLE for which corresponding disease-activity
data were available (that is, SLEDAI scores, anti-dsDNA
Abs, C3 and C4 levels, and ESR) indicates that elevated
heterotrimer levels may be associated with increasing SLE
disease activity (Supplemental Tables 1 and 2 in Addi-
tional file 2). Thus, further studies with larger group sizes
are warranted to pursue this possible correlation of het-
erotrimers with SLE disease activity. Indeed, a larger data-
set should be constructed to confirm data trends identified
in this study, and as disease levels may fluctuate for indivi-
dual patients, information on disease activity scores (at the
time of blood draw) should be collected, along with the
serum BLyS, APRIL, and heterotrimer levels.
In agreement with previous reports [15], our data also
show that BLyS is detectable in a higher fraction of
patients with SLE than in healthy controls. BLyS levels
also reportedly correlate with clinical disease activity in
SLE [39] and RA [25]. Levels of BLyS have been shown
to increase during anti-CD20 mAb-mediated B-cell
depletion in patients with both SLE and RA, and to
decline with B-cell repopulation in patients with SLE
[25,40]. Similar elevations in BLyS have also been
observed in sera from patients with Sjögren’ss y n d r o m e
and non-Hodgkin lymphoma treated with an anti-CD20
mAb [41,42]. In contrast, APRIL levels were reported to
decrease during anti-CD20 mAb-mediated B-cell deple-
tion in patients with SLE, whereas no significant
changes in APRIL levels were observed in patients with
RA undergoing anti-CD20 therapy [25]. To address the
discrepancies in reported APRIL data from various
laboratories, these studies are currently being repeated
using our validated APRIL ELISA assay.
Given that heterotrimers have similar binding proper-
ties and in vitro activities to the BLyS and APRIL homo-
trimers, and may be present in sera in similar amounts to
APRIL and BLyS, we postulate that they may likely play
similar biologic roles to BLyS and APRIL in B-cell devel-
opment and differentiation. As our recombinant A2B het-
erotrimers behave much like APRIL in vitro,w ea l s o
speculate that AB2 heterotrimers would function more
like BLyS, for example, playing a role in early B-cell survi-
val and selection. BLyS exists in both soluble and trans-
membrane-bound forms, whereas APRIL is believed to
exist only in a soluble form, with the exception of the
TWEAK-APRIL fusion protein TWE-PRIL [43]. We did
not test whether BLyS/APRIL heterotrimers were
expressed on the cell surface, but if so, their potential for
exerting biologic effects would presumably be expanded.
W h e t h e rn a t i v eh e t e r o t r i m e r sp l a yab i o l o g i cr o l ed i s t i n c t
from their homotrimeric counterparts remains to be deter-
mined. Our data suggest that investigating forms of BLyS
and APRIL other than the conventional homotrimers in
patients with autoimmune diseases may help to elucidate
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tional disease markers and targets for treatment.
Conclusions
Recombinant BLyS/APRIL heterotrimers are biologically
active in vitro on TACI-transfected cells and on primary
human B cells, and are inhibited by atacicept and
BCMA-Ig. A new heterotrimer assay that detects both
A2Ba n dA B 2 forms of BLyS/APRIL heterotrimers
demonstrated that native heterotrimers are elevated in
patients with SLE.
Further investigation of heterotrimer levels and their
apparent relation with disease activity is warranted in a
large cohort of patients with autoimmune diseases.
Mechanistic studies to determine if BLyS/APRIL heterotri-
m e r sp l a yab i o l o g i cr o l ed i s t i n c tf r o mB L y Sa n dA P R I L ,
and whether native heterotrimers are inhibited by BLyS-
and APRIL-targeting agents, would also be of interest.
Additional file 1: Supplemental methods. Additional methodologic
details.
Additional file 2: Supplemental tables. Supplemental Tables 1 and 2
show serum heterotrimer levels and disease-activity markers in a subset
of samples from patients with SLE.
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